ArticleFrontiers in oncology2024

Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China.

Zhonghua Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.